Efficacy of prednisone combined with mycophenolate mofetil for immunoglobulin A nephropathy with moderate-to-severe renal dysfunction

Abstract

BACKGROUND

Immunoglobulin A nephropathy (IgAN) is a common form of chronic glomerulonephritis. Currently, IgAN is one of the main causes of chronic renal failure in China; its prognosis varies greatly between patients, with renal function at the time of diagnosis and prognosis being strongly correlated. Mycophenolate mofetil (MMF) is a drug with a good immunomodulatory effect and is commonly used clinically. However, its effects in IgAN have not yet been clearly demonstrated. Therefore, herein, we retrospectively compared the effectiveness and safety of prednisone alone or combined with MMF for the treatment of primary IgAN with moderate-to-severe renal impairment.

AIM

To evaluate the effectiveness and safety of prednisone and MMF in treating IgAN with moderate-to-severe renal dysfunction.

METHODS

Between January 2011 and December 2020, 200 patients with moderate-to-severe IgAN were included in this study, all of whom were admitted to Wuxi People's Hospital affiliated with Nanjing Medical University. All patients underwent a renal puncture biopsy, which revealed primary IgAN with a glomerular filtration rate (GFR) of 30–60 mL/min. The patients were divided into a glucocorticoid therapy group (GTG) and an immunosuppressive therapy group (ITG) according to the different treatment regimens, with 100 patients in each group. Based on general treatments, such as angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers, patients in the GTG were administered prednisone 0.5–0.8 mg/ (kg·d^-1) for 4–8 wk, which was reduced by 5 mg every two weeks until the maintenance(30 mg/d) dose was reached and maintained for 12 mo. In the ITG, MMF was administered at 1.0 g/d for 6–12 mo, followed by a maintenance dosage of 0.5 g/d for 12 mo. Age, sex, blood pressure, 24-h urinary egg white measurement, serum creatinine (Scr), blood uric acid, blood albumin, blood potassium (K), hemoglobin, GFR, alanine aminotransferase, total cholesterol (T-CHO), fasting blood glucose, and body mass index were recorded. The 24-h urinary protein, Scr, and GFR levels were recorded 3, 6, 9, and 12 mo after treatment. Follow-up data were also collected.

RESULTS

No discernible differences existed between the two groups in terms of age, sex, blood pressure, creatinine, 24-h urinary protein level, GFR, or other biochemical indicators at the time of enrollment. Both regimens significantly reduced the 24-h urinary protein quantitation and stabilized renal function. Nine months after treatment, the 24-h urinary protein and Scr of the ITG decreased more significantly than those of the GTG. By the 12^th month of treatment, the 24-h urinary protein and Scr in both groups continued to decrease compared to those by the 9^th month. In addition, the overall response rate in the ITG was significantly higher than that in the GTG. The occurrence of side effects did not vary significantly between the two regimens; however, endpoint events were significantly more common in the GTG than in the ITG. The follow-up time for the GTG was noticeably lower than that for the ITG.

CONCLUSION

Prednisone combined with MMF was effective for the treatment of IgAN with moderate-to-severe renal dysfunction.

Key Words: IgAN; Moderate-to-severe decline in renal function; Prednisone; Mycophenolate; Treatment effect; Safety

Core Tip: In this study, the clinical and follow-up data of patients were retrospectively analyzed to explore the effectiveness and safety of prednisone combined with mycophenolate mofetil to guide the selection of clinical treatment of primary immunoglobulin A nephropathy (IgAN) with renal dysfunction. The results showed that mycophenolate ethyl ester combined with prednisone were more effective in treating patients with IgAN than prednisone alone, and could effectively improve renal function.

INTRODUCTION

Primary immunoglobulin A nephropathy (IgAN) refers to primary glomerulonephritis with a pathological manifestation of IgA-dominated immune complex deposition in the mesangial region after the exclusion of secondary factors[1,2]. IgAN is a primary glomerular disease that affects people worldwide; the typical age of disease onset is 20–40 years and it is more common in men. IgAN accounts for 45.26%–58.2% of the primary glomerular diseases in China[3,4]. Furthermore, IgAN is the primary condition most frequently causing end-stage renal disease (ESRD), accounting for 26.69% of cases. The pathogenesis of IgAN is extremely complex; the clinical and pathological manifestations are not the same and the prognosis is very different between patients. IgAN can clinically manifest as isolated microscopic hematuria, gross hematuria, renal involvement, elevated blood pressure, and massive proteinuria[5]. Pathologically, mesangial cell proliferation, focal segmental sclerosis, capillary hyperplasia, and renal tubulointerstitial disease are often observed and sometimes accompanied by crescent formation in IgAN[6]. Therefore, IgAN is currently considered a clinical syndrome that is characterized mainly by changes in renal immunopathology[7]. IgAN often progresses to ESRD, and the renal survival rates after 5 and 10 years of IgAN have been reported to be 85.1% and 77.1%, respectively, in China[8]. Approximately 15%–20% of patients with IgAN progress to ESRD 10 years after onset and 30%–40% progress to ESRD after 20 years[9].

Glucocorticoids have been used to treat IgAN for many years because they reduce inflammation and urinary protein excretion[10]. However, there have been few studies on the application of glucocorticoids in the management of renal dysfunction in patients with IgAN; therefore, the effectiveness of glucocorticoids in this subset of patients is still not supported by sufficient evidence in medical literature. Because the main feature of IgAN is a change in renal immunopathology, immunosuppressants are often used in clinical practice to treat the disease. Mycophenolate mofetil (MMF) is a drug with a good immunomodulatory effect and is commonly used clinically. It mainly inhibits T and B lymphocyte proliferation, interferes with cytotoxic T cell maturation and antibody production in B cells, exerts a strong immunosuppressive effect, and has been clinically utilized for the treatment of IgAN[11-13]. Currently, researchers and clinicians are advocating for hormone-free therapy to treat IgAN with immunosuppressants alone or immunosuppressants combined with low-dose hormones, particularly in patients with mild-to-moderate kidney injury, to reduce urinary protein, protect renal function, and not increase the incidence of adverse reactions. However, the results are inconsistent and there are many controversies. Therefore, in this study, we retrospectively compared the effectiveness and safety of prednisone combined with MMF and prednisone alone for the treatment of primary IgAN with moderate to severe renal impairment.

MATERIALS AND METHODS

Patient characteristics

Between January 2011 and December 2020, 200 patients with moderate-to-severe IgAN participated in this study, all of whom had been admitted to Wuxi People’s Hospital affiliated with Nanjing Medical University. All patients underwent a renal puncture biopsy that revealed primary IgAN with a glomerular filtration rate (GFR) of 30–60 mL/min. The patients were divided into two groups of 100 cases each: the immunosuppressive therapy group (ITG) and the glucocorticoid therapy group (GTG). Based on general therapy, such as angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), patients in the GTG were given 0.5–0.8 mg /(kg·d^-1) of prednisone for 4–8 wk, which was reduced by 5 mg every two weeks until the maintenance dosage (30 mg/d) was reached and maintained for 12 mo. In the ITG, based on the treatment regimen of the hormone therapy group, 1.0 g/d of MMF was administered for 6–12 mo; the maintenance dose was 0.5 g/d for 12 mo.

The inclusion criteria were as follows: (1) 18–60 years old; (2) primary IgAN diagnosed by renal biopsy; (3) moderate to severe impairment of renal function at diagnosis: 30 mL/min < GFR < 60 mL/min; (4) 24-h urinary protein quantification > 1.0 g; (5) the quantity of glomeruli obtained through renal biopsy was ≥ 10, and the proportion of glomerulosclerosis revealed by renal pathology was < 80%; tubule atrophy, and renal interstitial fibrosis > 30% and < 80%; and (6) complete clinical, pathological, and follow-up data were available.

The exclusion criteria were as follows: (1) Use of immunosuppressants or cytotoxic drugs; (2) necrotizing capillary vasculitis and crescent nephritis were found by renal biopsy, excluding purpura nephritis, ankylosing spondylitis, systemic lupus erythematosus, hepatitis B virus-associated nephritis, or other secondary IgAN; (3) patients with liver function impairment (aminotransferase increased by > 1.5 times), type 1 and type 2 diabetes mellitus, and patients with tumors; and (4) patients with a history of mental illness or cognitive impairment, and pregnant and lactating women.

Observational indicators

Prior information was gathered during renal biopsy. Age, sex, blood pressure, 24-h urinary egg white measurement, serum creatinine (Scr), blood uric acid, blood albumin (ALB), blood potassium (K), hemoglobin (Hb), estimated GFR (eGFR), alanine aminotransferase (ALT), T-CHO, fasting blood glucose (Glu), and body mass index (BMI) were measured. The 24-h urinary protein, Scr, and eGFR levels were recorded 3, 6, 9, and 12 mo after treatment. Follow-up data were collected, including of the duration of follow-up (if an endpoint event occurred then the patient was withdrawn from the follow-up) and of any adverse events, including pneumonia, leukopenia, anemia, gastrointestinal discomfort, decreased transaminase levels, and diabetes. The follow-up duration was 12 mo.

Evaluation criteria

The evaluation criteria were as follows: (1) Obvious effect: After treatment, the urinary protein quantity was < 0.3 g/d and Scr was not > 15% higher than the baseline value before treatment; (2) effective: The urinary protein quantity after treatment was still ≥ 0.3 g/d; however, it was > 50% lower than the baseline value, and the Scr was not > 15% higher than the baseline value before treatment; and (3) ineffective: Blood creatinine increased by > 15% from the baseline value before treatment, else the urine protein quantitation did not meet the above standards.

Endpoint events

The endpoint events were defined as follows: (1) Primary endpoint: during treatment follow-up, participants entered ESRD on dialysis or the eGFR decreased by > 50%; (2) safety endpoint: severe infection, liver function impairment, or other serious complications and comorbidities; and (3) patients quit or were lost during follow-up.

Statistical analysis

Statistical analyses were performed using SPSS 17.0 (IBM corporation, Armonk, NY, United States). Normally distributed measurement data are shown as mean ± standard deviation; non-normally distributed data are shown as the median. Categorical variables are described as rate. Chi-square analysis was performed to analyze the count data whereas the t-test was used to evaluate changes from pre- to post-treatment. The mean renal survival time was calculated using the Kaplan–Meier method. P values of < 0.05 were considered to indicate statistically significant differences.

RESULTS

Clinical characteristics

At the time of enrollment, there was no discernible variation in age, sex, blood pressure, 24-h urinary protein quantification, Scr, ALB, K, Hb, eGFR, ALT, T-CHO, Glu, or BMI between the two groups (P > 0.05), as shown in Table 1.

Table 1 Baseline data of patients in the different treatment groups.

Project	GTG	ITG	t value	P value
Male:Female	60:40	61:39	0.021	0.885
Age (yr)	33.15 ± 9.91	34.42 ± 10.04	-0.901	0.369
DBP (mmHg)	93.05 ± 6.98	93.03 ± 7.73	0.019	0.985
SBP (mmHg)	140.60 ± 9.94	141.40 ± 11.17	-0.535	0.593
K (mmol/L)	4.88 ± 0.97	4.72 ± 0.96	1.149	0.252
Hb (g/L)	128.60 ± 14.97	129.65 ± 16.29	-0.472	0.638
GFR (mL-1min-1∙(1.73∙m2)-1)	55.36 ± 3.34	54.70 ± 3.27	1.405	0.162
ALT (U/L)	36.53 ± 3.20	37.12 ± 3.30	-1.279	0.203
T-CHO (mmol/L)	5.59 ± 0.99	5.55 ± 0.99	0.321	0.748
Glu (mmol/L)	5.19 ± 0.69	5.10 ± 0.66	0.883	0.378
BMI (kg/m2)	23.06 ± 2.51	23.29 ± 2.55	-0.717	0.474
Alb (g/L)	22.94 ± 3.20	23.11 ± 3.02	-0.402	0.688
24-h urinary protein quantification (g)	4.01 ± 1.43	3.86 ± 1.37	0.76	0.448
Scr (μmol/L)	121.51 ± 14.58	122.16 ± 15.29	-0.311	0.756

GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group; DBP: Diastolic blood pressure; SBP: Systolic blood pressure; Scr: Serum creatinine; UA: Blood uric acid; BLA: Blood albumin; K: Blood potassium; Hb: Hemoglobin; eGFR: Glomerular filtration rate; ALT: Alanine aminotransferase; T-CHO: Total cholesterol; Glu: Fasting blood glucose; BMI: Body mass index.

Changes in renal function and proteinuria before and after treatment in both groups

As shown in Table 2, from 3 to 12 mo after treatment, 24-h urinary protein quantitation in both groups began to decrease from baseline values with statistical significance (P < 0.05). However, at 9 mo after treatment, the 24-h urinary protein quantitative level of the ITG decreased more significantly than that of the GTG (P < 0.05). By the 12^th month after treatment, the 24-h urinary protein levels in both groups continued to decrease compared with those by the 9^th month, as shown in Figure 1A. Similar to the 24-h urinary protein quantitation, Scr in both groups began to decline from baseline 3 to 12 mo after treatment (P < 0.05). However, the Scr level of the ITG decreased more significantly than that of the GTG at 9 mo after treatment (P < 0.05). At 12 mo after treatment, Scr levels in both groups continued to decline compared to that by 9 mo after treatment, as shown in Figure 1B.

Figure 1 Changes in renal function and proteinuria before and after treatment in both glucocorticoid therapy group and immunosuppressive therapy group. A: Changes in the trend of urinary protein quantity over 24 h of treatment in the two groups; B: Change in the trend of serum creatinine in the two groups over time. ^aP < 0.05 compared to glucocorticoid therapy group (GTG). ^bP < 0.01 compared to GTG. GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group.

Table 2 Renal function and proteinuria before and after treatment in both groups.

Project	Time	GTG	ITG	t value	P value
24-h urinary protein quantification (g)	Before the treatment	4.01 ± 1.43	3.86 ± 1.37	0.597	0.551
	3 mo after treatment	2.57 ± 0.69a	2.40 ± 0.91a	1.192	0.236
	6 mo after treatment	1.62 ± 0.67a	1.54 ± 0.75a	0.632	0.529
	9 mo after treatment	1.09 ± 0.61a	0.89 ± 0.50a	1.985	0.049
	12 mo after treatment	0.68 ± 0.38a	0.39 ± 0.42a	4.062	< 0.001
Scr (μmol/L)	Before the treatment	121.51 ± 14.58	122.16 ± 15.29	0.244	0.808
	3 mo after treatment	113.02 ± 21.63a	112.00 ± 24.72a	0.247	0.805
	6 mo after treatment	108.15 ± 35.2 a	105.99 ± 34.22a	0.34	0.72
	9 mo after treatment	96.81 ± 34.60 a	82.23 ± 31.41a	2.454	0.016
	12 mo after treatment	80.30 ± 7.45 a	64.76 ± 18.32 a	11.053	< 0.001

^aP < 0.05, compared to before treatment.

GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group; Scr: Serum creatinine.

Comparison of the curative effect between the two groups

As shown in Table 3, in the GTG, 21 cases showed an obvious curative effect and treatment was effective in 45 cases with a total effective rate of 66%. In the ITG, 15 cases showed an obvious curative effect and treatment was effective in 65 cases with a total effective rate of 80%. The total effective rates of the two groups were statistically significant (P < 0.05).

Table 3 Comparison of efficacy between the two groups (%).

Project	Ineffective	Obvious effect	Effective	Total effective rate
GTG	34	21	45	66
ITG	20	15	65	80
χ2				4.972
P value				0.026

GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group.

Prognostic analysis

To further evaluate the efficacy of therapy in both groups, the incidence of endpoint events was assessed, and the patients in both groups were followed up with for 12 mo. As shown in Table 4 and Figure 2, in the GTG, renal endpoint events occurred in 14 patients, safety endpoint events occurred in 18 patients, with an incidence of endpoint events was 32%. In the ITG, renal endpoint events occurred in seven patients, safety endpoint events occurred in 12 patients, and the incidence of endpoint events was 19%. There was a statistically significant difference in the incidence of endpoint events between the two groups (P < 0.05). The follow-up time of the GTG and ITG were 10.11 ± 3.09 and 11.07 ± 2.08 mo, respectively. A statistically significant difference was observed between the two groups (P < 0.05).

Figure 2 Kaplan–Meier survival curves of patients with no endpoint events in the glucocorticoid therapy group and immunosuppressive therapy group. GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group.

Table 4 Prognosis of patients in the two groups.

Project	GTG	ITG	χ2	P value
Renal endpoint	14	7
Serious infection	4	2
Serious liver injury	4	2
Serious complication	10	8
Incidence of endpoint events	32%	19%	4.448	0.035
Follow-up time (mo)	10.11 ± 3.09	11.07 ± 2.08	2.000	0.048

GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group.

Safety analysis

From the treatment period to the end of the follow-up period, in the GTG, 18 patients had gastrointestinal reactions, 15 had anemia, 11 had pneumonia, 13 had elevated transaminase levels, 13 had leukopenia, and 11 had diabetes. In the ITG, 22 patients had gastrointestinal reactions, 24 had anemia, 18 had pneumonia, 17 had elevated transaminase, 12 had leukopenia, and 12 had diabetes. The frequency of adverse reactions did not differ significantly between the two groups, as shown in Table 5.

Table 5 Occurrence of adverse reactions in the two groups.

Project	GTG	ITG	χ2	P value
Gastrointestinal reaction	18	22	0.50	0.480
Anemia	15	24	2.580	0.108
Pneumonia	11	18	1.976	0.160
Transaminitis	13	17	0.627	0.428
Leukocytopenia	13	12	0.046	0.831
Diabetes	11	12	0.049	0.825

GTG: Glucocorticoid therapy group; ITG: Immunosuppressive therapy group.

DISCUSSION

Primary IgAN is a disease with various clinicopathological manifestations, and its prognosis differs owing to these different manifestations. The Kidney Disease: Improving Global Outcomes (KDIGO) Guidelines for glomerulonephritis considers large proteinuria, hypertension, decreased eGFR, and severe renal pathological changes at initiation and follow-up as potential contributors to the development of renal disease[14]. However, there is currently no unified treatment plan for IgAN, and only IgAN crescent body nephritis with clear indications for cyclophosphamide application is indicated in the guidelines. For patients who have IgAN with renal impairment, particularly those with eGFR values of 30–60 mL/min, no consensus exists on whether further aggressive treatment is required.

The pathogenesis of IgAN has not been clearly defined clinically, and abnormal immune mechanisms and inflammatory injury are believed to be the main pathogenic factors[5,15,16]. In the past, it was clinically considered to be a benign process that did not require intervention; however, in-depth research showed that it was a non-benign process with progressive lesions and even caused end-stage renal failure. However, clinical treatment plans differ; the main treatment is symptomatic treatment[17-19]. Methylprednisolone (MP) is a commonly-used glucocorticoid[20]. By regulating the synthesis and metabolism of proteins, sugars, and fats, MP can exert anti-inflammatory, antiviral, and anti-shock effects, and inhibit the immune response[21,22]. It can also act on the renin-angiotensin system and inhibit kidney lesions by binding to amino acids in the transmembrane region of angiotensin II[23]. Alleviation of renal interstitial fibrosis and glomerulosclerosis can delay the progression of kidney disease, and the treatment effect is accurate. However, studies have shown that MP increases the risk of serious adverse events, and in the early stage, it can increase the level of blood creatinine and affect the prognosis[24,25].

MMF is a new type of immunosuppressant that is used mainly to prevent organ transplantation rejection, not to treat IgAN; however, it was found that MMF has a certain effect on IgAN[26,27]. In this study, we further evaluated the efficacy and safety of glucocorticoids combined with morphol mycophenate in patients with IgAN at risk of progression based on strict blood pressure control using ACEI/ARB and other antihypertensive agents. There were no noteworthy differences between the two groups in terms of age, sex, blood pressure, creatinine, 24-h urinary protein level, eGFR, and other biochemical indicators at the time of enrollment. At baseline, patients in both groups had higher Scr and 24-h urinary protein quantification levels and lower eGFR and albumin levels, suggesting a higher risk of disease progression. A comparison of prednisone alone and prednisone combined with moxylmycophenate revealed that both treatments significantly reduced the 24-h urinary protein levels and stabilized renal function during treatment. The statistical results showed that at 9 mo after treatment, the 24-h urinary protein quantity and Scr of the ITG decreased more significantly than that of the GTG (P < 0.05). By the 12^th month after treatment, the 24-h urinary protein and Scr in both groups continued to decrease compared with those by the 9^th month. In addition, the overall response rate of the ITG was 80%, which was significantly higher than that of the GTG (69%). These results indicate that the combination of mycophenolate and prednisone in patients with IgAN is more effective than prednisone alone and can effectively improve renal function.

After absorption, MMF selectively acts on hypoxanthine mononucleotide dehydrogenase, blocks guanine nucleotide synthesis, and plays an anti-inflammatory role by inhibiting the synthesis of cell surface adhesion molecules[28]. It can also inhibit an increase in the numbers of fibroblasts, endothelial cells, and vascular smooth muscle cells and reduce the decline in renal function caused by damage to the renal parenchyma[29]. Combined treatment with MP can play a synergistic role, improve the clinical therapeutic effects, and effectively improve kidney function. MMF also has the advantages of low toxicity and fewer side effects, which can effectively prevent and treat glomerulosclerosis[30]. In this study, the frequency of adverse reactions did not significantly differ between the two treatment regimens; however, compared with the incidence of endpoint events in the ITG (19%), that in the GTG was 32%, which is a noticeable increase. The follow-up time of the GTG (10.11 ± 3.09 mo) was significantly lower than that of the ITG (11.07 ± 2.08 mo). These results suggest that the safety of mycophenate combined with prednisone in the treatment of IgAN is attributed to prednisone alone.

There are several limitations of this study; for instance, the sample size was small and the follow-up time of patients was short. We believe that it is necessary to carry out future studies with a large sample and long-term follow-up, and observe the efficacy, recurrence, and adverse reactions of patients according to the degree of renal impairment or according to the kidney pathological grade.

CONCLUSION

In summary, prednisone combined with mycophenolate ethyl ester for the treatment of IgAN with moderate-to-severe renal function decline has a significant therapeutic effect, can effectively improve renal function, has high security, and can be used as an optimized treatment plan in clinical practice.

ARTICLE HIGHLIGHTS

Research background

Immunoglobulin A nephropathy (IgAN) accompanied with renal dysfunction is a common disease. There is no standard treatment for IgAN with renal dysfunction, and glucocorticoid therapy is usually administered. However, single glucocorticoid is not a complete response of IgAN with renal dysfunction. IgAN is a disease characterized by abnormal immune system, which may be due to glomerular pathological damage caused by the deposition of IgA or its circulating immune complexes in the glomerulus. Therefore, treatment with glucocorticoid and immunosuppressive drugs may be more effective for patients with IgAN with renal dysfunction.

Research motivation

IgAN is among the most prevalent primary glomerular diseases worldwide. Among primary glomerular diseases in China, IgAN accounts for 45.26%–58.2%. Furthermore, as the most prevalent primary cause of ESRD, IgAN accounts for 26.69% of ESRD cases. Glucocorticoids have been used in IgAN for many years because they have advantageous effects on reducing inflammation and urinary protein excretion. The main feature of IgAN is a change in renal immunopathology, which is often treated with immunosuppressants. Therefore, it is important to research the moderate-to-severe IgAN therapy of glucocorticoids combined with immunosuppressants.

Research objectives

To explore the efficacy and security of prednisone combined with mycophenolate mofetil in IgAN therapy with moderate-to-severe renal dysfunction. We hope that, a safer and more effective treatments will be developed.

Research methods

This study included 200 patients with moderate-to-severe renal dysfunction and IgAN patients. All patients were divided into the glucocorticoid therapy group (GTG) and immunosuppressive therapy group (ITG) according to different treatment regiments, with 100 patients in each group. The baseline data and follow-up data of patients who underwent kidney biopsy were collected. Finally, the above data were compared and analyzed.

Research results

The baseline data before treatment were not significantly different between groups. After treatment, serum creatinine and 24-h urinary protein levels in both groups decreased, but the decrease in the ITG differed from that in the GTGs in the 9^th month. In addition, the overall response rate in the ITG was significantly higher than that in the GTG. The GTG had more endpoint events than the ITG, but the adverse reactions were similar between the regimens.

Research conclusions

The addition of immunosuppressants on the basis of glucocorticoids is a better treatment option for moderate-to-severe renal dysfunction in patients with IgAN.

Research perspectives

Future research will involve large-scale sample-controlled studies and long-term follow-up, and will track outcomes, relapse rates, and side effects of patients in relation to their level of renal impairment or pathological grade of their kidneys.